FDA approves CV event risk reduction indication for icosapent ethyl



The FDA on Friday approved the use of icosapent ethyl as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels, according to an agency press release.
Patients must also have either established CVD or diabetes and two or more additional risk factors for CVD.
Icosapent ethyl (Vascepa, Amarin) is the first FDA-approved drug to reduce CV risk among adults with elevated triglycerides as an add-on to maximally tolerated statin therapy.
The drug first netted approval in July 2012 for the reduction of triglycerides in adults with severe



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.